Alexander Sasha Vlassov,
Senior Manager R&D ,
Thermo Fisher Scientific
Alexander “Sasha” Vlassov is a Senior Manager R&D at Thermo Fisher Scientific. Dr. Vlassov has developed multiple product lines including reagents for exosome research, microbiome research, siRNA, miRNA mimics/inhibitors, and transfection reagents. Currently, he is focusing on development of advanced technologies for exosome analysis and improved methods for extracting nucleic acids from clinically relevant samples. Prior to joining Thermo Fisher, he was holding various Research & Development positions at Life Technologies, Invitrogen, Applied Biosystems and Somagenics; Postdoctoral fellow at UC Boulder (Colorado), visiting scientist at IBMC (France) and research scientist at ICBFM (Russia). During his scientific career, Dr. Vlassov co-authored over 70 publications and 8 patents.
An Optimized Procedure for Exosome Isolation and Analysis Using Serum Samples: Application to Cancer Biomarker Discovery
Tuesday, 17 November 2015 at 14:30
Add to Calendar ▼2015-11-17 14:30:002015-11-17 15:30:00Europe/LondonAn Optimized Procedure for Exosome Isolation and Analysis Using Serum Samples: Application to Cancer Biomarker DiscoverySELECTBIOenquiries@selectbiosciences.com
Exosomes are RNA and protein-containing nanovesicles secreted by all cell types and found in abundance in body fluids, including blood, urine and cerebrospinal fluid. These vesicles seem to be a perfect source of biomarkers, as their cargo largely reflects the content of parental cells, and exosomes originating from all organs can be obtained from circulation through minimally invasive or non-invasive means. Here we describe an optimized procedure for exosome isolation and analysis using clinical samples, starting from quick and robust extraction of exosomes with Total exosome isolation reagent, then isolation of RNA followed by qRT-PCR. Effectiveness of this workflow is exemplified by analysis of the miRNA content of exosomes derived from serum samples – obtained from the patients with metastatic prostate cancer, treated prostate cancer patients who have undergone prostatectomy, and control patients without prostate cancer. Three promising exosomal microRNA biomarkers were identified, discriminating these groups: hsamiR375, hsa-miR21, hsa-miR574.
Add to Calendar ▼2015-11-16 00:00:002015-11-17 00:00:00Europe/LondonBiofluid BiopsiesSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2015-11-17 14:30:002015-11-17 15:30:00Europe/LondonAn Optimized Procedure for Exosome Isolation and Analysis Using Serum Samples: Application to Cancer Biomarker DiscoverySELECTBIOenquiries@selectbiosciences.com.jpg)
